Synlogic (NASDAQ:SYBX) had its price target raised by equities researchers at HC Wainwright from $20.00 to $22.00 in a report released on Tuesday, The Fly reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 184.97% from the company’s current price.

A number of other research firms have also weighed in on SYBX. Zacks Investment Research lowered HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Chardan Capital set a $10.00 target price on Arcimoto and gave the company a “buy” rating in a report on Friday, April 12th. Wedbush restated an “outperform” rating and issued a $21.00 target price on shares of Epizyme in a report on Wednesday, June 12th. Piper Jaffray Companies set a $173.00 target price on DexCom and gave the company a “buy” rating in a report on Monday. Finally, Jefferies Financial Group dropped their target price on CommVault Systems to $65.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $20.00.

Shares of Synlogic stock opened at $7.72 on Tuesday. Synlogic has a 52 week low of $5.75 and a 52 week high of $14.59. The company has a quick ratio of 11.53, a current ratio of 11.53 and a debt-to-equity ratio of 0.20. The firm has a 50 day moving average price of $8.25. The firm has a market capitalization of $195.49 million, a PE ratio of -3.80 and a beta of 2.42.

Synlogic (NASDAQ:SYBX) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.03. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $0.42 million. As a group, analysts expect that Synlogic will post -2.09 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Northern Trust Corp lifted its holdings in Synlogic by 1.2% during the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock worth $1,172,000 after acquiring an additional 2,005 shares during the period. Alps Advisors Inc. lifted its holdings in Synlogic by 4.5% during the first quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 2,658 shares during the period. Bank of New York Mellon Corp lifted its holdings in Synlogic by 12.1% during the fourth quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 6,129 shares during the period. Rhumbline Advisers lifted its holdings in Synlogic by 45.7% during the fourth quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 6,820 shares during the period. Finally, Bank of Montreal Can lifted its holdings in Synlogic by 5,743.1% during the first quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 12,520 shares during the period. Institutional investors own 81.89% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

See Also: What are some reasons analysts would give stocks a buy rating?

The Fly

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.